Pre-Conference Symposia – International Stroke Conference

Pre-Con Symposia Schedules

All times are Mountain Standard Time (MST) (GMT -7)

2024 HEADS-UP: Health Equity and Actionable Disparities in Stroke: Understanding and Problem Solving
Tuesday, February 6, 2024
8:30 a.m. to 5:45 p.m. MT

A separate registration is required to attend the Pre-Conference Symposia.

Open HEADS-UP in Online Program Planner (new window)

This symposium is a multidisciplinary scientific forum focused on race-ethnic disparities in cerebrovascular disease, with the overarching goal of reducing disparities in stroke and accelerating translation of research findings to improve outcomes for race-ethnic minorities who reside in the US. HEADS-UP is a collaborative initiative with the American Stroke Association (ASA), a national organization "dedicated to advancing the science of stroke prevention, treatment and recovery through research and education", and the National Institutes for Neurological Disorders and Stroke (NINDS). In addition to exciting lectures being given by leaders in this field, twenty early career scholars will present their disparities research work at a dedicated poster session as well as participate in career development sessions. A plenary lecture in honor of the late Edgar Kenton, MD will be given by an outstanding researcher selected by the HEADS-UP Program Committee, with a solid track record of studying or addressing stroke disparities.

Amytis Towfighi, MD, Los Angeles, CA
Janet A Prvu Bettger, ScD, FAHA, Durham, NC

HEADSUP 2024 Schedule
Time Activity
8:30 a.m. Welcome, Pre-test, Policy Maker Introduction
8:35 a.m. Distinguished Lecture: Advancing Stroke Policy
Sheila Cristina Ouriques Martins, Porto Alegre, Brazil
8:55 a.m. Q&A
9:00 a.m. to 10:00 a.m. Moderator:
Mathew J Reeves, PhD, East Lansing, MI
9:00 a.m. Measurement Presentation 1: Developing the Underlying Evidence Needed for Effective Policy Change
9:15 a.m. Measurement Presentation 2: US Stroke Care Measurement, Health Disparities and Policy
Lee H Schwamm, MD, FAAN, FAHA, FANA, New Haven, CT
9:30 a.m. Measurement Presentation 3: National Stroke Care Measurement, Health Disparities and Policy
Dominique Cadilhac PhD, MPH, BN, RN, FWSO, FESO, Clayton, Australia
9:45 a.m. Measurement Panel Q&A
10:00 a.m. Break
10:15 a.m. Introduction to the Edgar J Kenton III Lecture
Amytis Towfighi, MD, Los Angeles, CA
10:18 a.m. Kenton Lecture
Bernadette Boden, PhD, Irvine, CA
10:38 a.m. Q&A
10:45 a.m. to 12:00 p.m. Think Tank on Works in Progress (WIP - Career Development Session)
Cheryl Bushnell, MD, MHS, FAHA, Winston Salem, NC
James Burke, MD MS, Columbus, OH
10:45 a.m. ACCESS: Improving ACCess and Equity among Stroke Survivors
Christine Groves, MD, MPH, FAAPMR, Indianapolis, IN
11:00 a.m. WIP 2 with Q&A
Sara Hassani, MD, Durham, NC
11:15 a.m. Developing a Coaching Intervention for Individuals and Cardiovascular Disease
Setareh Akhvan, California
11:30 a.m. Prevalence and Predictors of Antidepressant Prescriptions During Hospitalization for Acute Stroke/TIA At a Large Academic Hospital
Hely D. Nanavati, MBBS, MPH, Birmingham, AL
11:45 a.m. Partnering with Patients and the Community to Improve Post-Stroke Blood Pressure
Rachel Forman, MD, New Haven, CT
12:00 p.m. Networking Lunch
1:00 p.m. Introduction to NINDS Speaker
Amytis Towfighi, MD, Los Angeles, CA
1:03 p.m. NINDS Speaker
Richard Benson, MD, PhD, FAAN, Bethesda, MD
1:15 p.m. HEADS-UP Poster Session
Poster Professors:
Lesli Skolarus, MD, MS, Chicago, IL
Virginia Howard, PhD, Birmingham, AL
Salina Waddy, MD, FAHA, Washington, DC

20 Poster Abstracts to be presented; see the Online Program Planner (new window)(link opens in new window) for titles and presenters.
3:15 p.m. Break
3:30 p.m. to 4:30 p.m. Partnerships to Advance Policy and Address Stroke Disparities
Moderators: TBA
3:30 p.m. Partnerships Presentation 1: Primary Stroke Prevention Worldwide: Translating Evidence into Action
3:45 p.m. Partnerships Presentation 2: Integrating Patients and Policy Makers
Mitchell Elkind, MD, MS, FAHA, New York, New York
4:00 p.m. Partnerships Presentation 3: Engaging NGOs
4:15 p.m. Partnerships Q&A
4:30 p.m.

Building Momentum (Career Development Session)
Becoming a Health Disparities Researcher Panelists:
Bruce Ovbiagele, MD, MSc, MBA, MLS, San Francisco, CA
Dawn O Kleindorfer, MD, FAHA, Ann Arbor, MI
Mai N Nguyen-Huynh, MD, MAS, FAHA, Walnut Creek, CA
Brett M Kissela, MD, MS, FAHA FAAN, Cincinnati, OH

5:30 p.m. Closing Remarks, Post-test, & Adjourn
Janet A Prvu Bettger, ScD, FAHA, Durham, NC

2024 Stroke in the Real World
Tuesday, February 6, 2024
9:00 a.m. to 5:00 p.m.

A separate registration is required to attend the Pre-Conference Symposia.

Open Stroke in the Real World in Online Program Planner (new window)(link opens in new window)

At this year’s Stroke in the Real World Pre-Con session, we will focus on stroke in select populations: women (including transwomen), individuals with cancer, and the young. We will discuss how membership in these groups affects stroke incidence, presentation, and care. Come listen and have the opportunity to interact with experts in the field to discuss a breadth of fascinating and useful stroke topics, ranging from acute to chronic care and from bread-and-butter presentations to rare presentations. You won’t want to miss this session!

Mollie McDermott, MD, MS, Ann Arbor, MI
Theodore Wein, MD, FRCPC, Mont-Royal, QC, Canada

Stroke in the Real World Schedule
Time Activity
8:00 a.m. Introduction
Mollie McDermott, MD, MS, Ann Arbor, MI
8:05 a.m. Overview of Pediatric Stroke
Jose Torres, MD, New York, NY
8:50 a.m. Race-Ethnic Differences in Risk Factors for Stroke in the Young
Lakeisha Mixon, MSW, LCSW-C, Baltimore, MD
9:20 a.m. Mental Health after Stroke in Women and the Young
M. Patrice Lindsay, RN, BScN, PhD, FWSO, Toronto, ON, Canada
9:50 a.m. Break
10:00 a.m. Stroke in Transwomen
Nicole Rosendale, MD, San Francisco, CA
10:30 a.m. Hormone Exposure and Stroke Risk
Malveeka Sharma, MD, Seattle, wa
11:00 a.m. Management of Carotid Disease in Women
Michel Shamy, MD, MA, FRCPC, Ottawa, ON, Canada
12:00 p.m. Lunch
1:00 p.m. Acute Presentations/Treatment/Outcomes of Stroke in Women
Tracy Masden, MD, PhD, FACEP, FAHA, Providence, RI
1:45 a.m. Epidemiology of Stroke in Malignancy
Deborah Siegal, MD, MSc, FRCPC, Ottawa, ON, Canada
2:15 p.m. Thrombolysis in Active Malignancy
Joseph Carrera, MD, Ann Arbor, MI
2:45 p.m. Thrombolysis in Active Malignancy
Parneet Grewal, MD, Charleston, SC
3:15 p.m. Break
3:30 p.m. Secondary Stroke Prevention in Active Malignancy
Babak B. Navi, MD, MS, Westport, CT
4:00 p.m. Immigration Status and Stroke
Manav V. Vyas, MBBS, MSc, PhD, FRCPC, Toronto, ON, Canada
4:30 p.m. Interventions for Stroke in Immigrant Populations
Imama A. Naqvi, MS, MS, New York, NY
4:55 p.m. Closing Remarks
Theodore Wein, MD, FRCPC, Mont-Royal, QC, Canada

2024 Stroke in the Lab World
Tuesday, February 6, 2024
9:00 a.m. to 5:30 p.m.

A separate registration is required to attend the Pre-Conference Symposia.

Open Stroke in the Lab World in Online Program Planner (new window)(link opens in new window)

Preclinical translational stroke research is at a crossroads. Exploratory animal experimentation in stroke therapy development has not predicted clinical outcomes. Therefore, we are facing a challenge in selecting the best and most relevant candidates for clinical trials in ischemic stroke. The established system of exploratory preclinical therapeutic testing in stroke is problematic. There are concerns over the design and execution of studies, their reproducibility, and generalizability. Over decades, investigators have deviated from sound scientific principles under impact, funding, and peer pressure, raising concern about the predictive value of animal experimentation in stroke therapy development. Urgent issues include 1) elimination of bias, 2) accountability of all animals, 3) incorporation of relevant biological variables, and 4) quality control.

To tackle these issues, independent, unbiased, and streamlined multicenter preclinical trial platforms are needed, with impartial funding, centralized blinding, randomization, independent data analysis, accountability, and quality control. The recognition and urgency of this unmet need has created momentum in planning and launching multicenter preclinical trial platforms in the US and Europe.

However, unlike clinical trials, the preclinical trial methodology is not established, and numerous issues remain unresolved, such as standardization for increased statistical power versus allowing natural heterogeneity to mimic real-world conditions better, methods for randomization and blinding, appropriate models and readouts, etc. A global consensus is needed, including common data elements to maximize the utility of the large amounts of data generated for future analyses across platforms.

This topic is both timely and appropriate for a premeeting all-day basic and translational science symposium at the ISC2024. We aim for international representation, opportunities for juniors to participate, and in-depth discussions on dedicated sessions on the most pressing and thorny issues facing preclinical trialists.

Cenk Ayata, MD, PhD, Charlestown, MA

Stroke in the Lab World Schedule
Time Activity
9:00 a.m. Welcome
Cenk Ayata, MD, PhD, Charlestown, MA
9:15 a.m. NIH Priorities for Translation in Stroke
Francesca Bosetti, PharmD, PhD, Rockville, MD
9:30 a.m. Innovations in Addressing the Translational Knowledge Gap
Emily Sena, PhD, Edinburgh, United Kingdom
9:45 a.m. Discovery vs. Confirmatory Testing
Claire Gibson, BSC, Nottingham, United Kingdom
10:00 a.m. Selecting the Best Candidates for Confirmative Pre-Clinical Studies
Johannes Boltze, MD, PhD, Coventry, United Kingdom
10:15 a.m. Discussion
10:45 a.m. Break
11:00 a.m. Should We Mimic Clinical Trials? Do We Need a New Design for Preclinical Trials?
Clinton Wright, MD, MS, FAHA, Rockville, MD
11:15 a.m. Which/How Many Stroke Models/Species to Employ?
Jaroslaw (Jarek) Aronowski, PhD, MD, Houston, TX
11:30 a.m. Which Comorbid Models (Age, Sex, HFD, HTN)?
Marilyn J. Cipolla, PhD, FAHA, Burlington, VT
11:45 a.m. Standardization vs. Heterogeneity? What to Control For?
Cenk Ayata, MD, PhD, Charlestown, MA
12:00 p.m. Statistical Models
Marcio A Diniz, PhD, New York City, NY
12:15 p.m. Discussion 
12:45 p.m. Lunch 
2:00 p.m. Clinical Correlation vs. Species-Specific Readouts?
Lauren H. Sansing, MD, MS, FAHA, FANA, New Haven, CT
2:15 p.m. Neurological Readouts: Which Tests?
Louise D McCullough, MD, PhD, FAHA, Houston, TX
2:30 p.m.  Tissue Readouts: From Histology to Imaging
Fahmeed Hyder, PhD, New Haven, CT
2:45 p.m.  Artificial Intelligence in Outcome Assessments
Ryan P. Cabeen, PhD, Los Angeles, CA 
3:00 p.m.  How to Handle Mortality as an Outcome and a Confounder?
Sarah McCann, PhD, Germany
3:15 p.m. Discussion
3:30 p.m. Break
4:00 p.m. Infrastructure Challenges: Randomization, Blinding, Tracking, Data Storage, Analysis
Patrick D. Lyden, MD, FAHA, Los Angeles, CA
4:15 p.m. Harmonization of Outcome Readouts Across a Network
Stefano Fumagalli, PhD, Italy
4:30 p.m. Common Data Elements
Raymond C Koehler, PhD, FAHA, Baltimore, MD
4:45 p.m. Medium, Format, and Principles for Sharing the Outcomes with the Community
Francesca Bosetti, PharmD, PhD, Rockville, MD
5:00 p.m. Discussion